[{"orgOrder":0,"company":"Oranomed","sponsor":"RadioMedix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oranomed \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Crescendo Biologics Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Crescendo Biologics Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Crescendo Biologics Ltd"},{"orgOrder":0,"company":"Oranomed","sponsor":"48Hour Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Oranomed","highestDevelopmentStatusID":"3","companyTruncated":"Oranomed \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Oranomed","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Oranomed","sponsor":"RadioMedix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Alphamedix","moa":"Somatostatin receptor (SSTR)","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"RadioMedix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0.35999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Oranomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"212-Pb DOTAM-GRPR1","moa":"GRPr","graph1":"Oncology","graph2":"Phase I","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oranomed \/ Inapplicable"},{"orgOrder":0,"company":"Oranomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"212-Pb DOTAM-GRPR1","moa":"GRPr","graph1":"Oncology","graph2":"Phase I","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oranomed \/ Inapplicable"},{"orgOrder":0,"company":"Oranomed","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MP0712","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Oranomed","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Molecular Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"MP0712","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Molecular Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Oranomed

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Sanofi will be responsible for the global commercialization of AlphaMedix (212Pb-DOTAMTATE), while Orano will manufacture AlphaMedix through its global industrial platform currently under development.

                          Product Name : Alphamedix

                          Product Type : Peptide

                          Upfront Cash : $111.6 million

                          December 09, 2024

                          Lead Product(s) : 212-Pb Dotamtate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Sanofi

                          Deal Size : $357.1 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy for unresectable, metastatic gastroenteropancreatic neuroendocrine tumors, naïve to peptide receptor therapy.

                          Product Name : Alphamedix

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : 212-Pb Dotamtate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : RadioMedix

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : MP0712 is a DLL3-targeting radio-DARPin therapy candidate, which is currently being evaluated for the treatment of

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 06, 2024

                          Lead Product(s) : MP0712

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Molecular Partners

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The agreement aims to combine Sanofi and Orano's expertise against rare cancers and accelerate the development of next-generation radioligand medicines based on 212Pb alpha-emitting isotopes.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The collaboration focuses on exemplify the benefit of Orano Med’s Targeted Alpha Therapies, using Humabody VH for precise targeting.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 07, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Crescendo Biologics Ltd

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Partnership aims to harness the potent properties of lead-212 (212Pb), a rare alpha-emitting radioisotope, in conjunction with 48Hour Discovery’s innovative peptide discovery technology and expertise.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : 48Hour Discovery

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The Collaboration focuses on developing novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to kill cancer cells selectively.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 01, 2024

                          Lead Product(s) : MP0712

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Molecular Partners

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the collaboration, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Orbit Discovery

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitt...

                          Product Name : Alphamedix

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 16, 2023

                          Lead Product(s) : 212-Pb Dotamtate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : RadioMedix

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : 212Pb-GRPR is a 212Pb-conjugated anti-GRPR (Gastrin-Releasing Peptide Receptor) targeting different types of solid tumors including several breast and prostate cancers tumor types.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          April 01, 2023

                          Lead Product(s) : 212-Pb DOTAM-GRPR1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank